Reuters logo
1 个月内
BRIEF-GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​
2017年6月12日 / 上午11点15分 / 1 个月内

BRIEF-GlaxoSmithKline announces positive results from two phase III studies of Tafenoquine​

1 分钟阅读

June 12 (Reuters) - GlaxoSmithKline Plc

* ‍GSK and Medicines for Malaria Venture announced positive results from two phase III studies of Tafenoquine​

* Tafenoquine is an investigational 8-aminoquinoline, for prevention of relapse of plasmodium vivax (p.vivax) malaria​

* Headline results show single-dose of 300mg tafenoquine reduced risk of relapse in patients with p.vivax malaria​

* ‍Study met its primary endpoint

* ‍study showed that a statistically significant greater proportion of patients treated with tafenoquine (60%) remained relapse-free over 6-month follow-up period​

* ‍GSK plans to progress regulatory filings for prevention of relapse of p. Vivax malaria later in 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below